Joy Yang Ge

831 total citations
34 papers, 604 citations indexed

About

Joy Yang Ge is a scholar working on Oncology, Otorhinolaryngology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Joy Yang Ge has authored 34 papers receiving a total of 604 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 13 papers in Otorhinolaryngology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Joy Yang Ge's work include Cancer Immunotherapy and Biomarkers (26 papers), Head and Neck Cancer Studies (13 papers) and Cancer Diagnosis and Treatment (9 papers). Joy Yang Ge is often cited by papers focused on Cancer Immunotherapy and Biomarkers (26 papers), Head and Neck Cancer Studies (13 papers) and Cancer Diagnosis and Treatment (9 papers). Joy Yang Ge collaborates with scholars based in United States, Canada and Taiwan. Joy Yang Ge's co-authors include Robert Bachman, David Michelson, Christopher Assaid, David W. Dodick, Richard B. Lipton, Tiffini Voss, Sheena K. Aurora, Amita Patnaik, Shirish M. Gadgeel and James Stevenson and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Joy Yang Ge

32 papers receiving 592 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joy Yang Ge United States	11	362	190	175	150	112	34	604
Yasutsugu Yamanaka Japan	11	110 0.3×	110 0.6×	44 0.3×	30 0.2×	106 0.9×	29	444
Yiming Chen China	10	93 0.3×	38 0.2×	89 0.5×	21 0.1×	38 0.3×	31	346
Gongfu Zhou United States	12	140 0.4×	120 0.6×	68 0.4×	27 0.2×	32 0.3×	23	428
Thomas Anderson United States	5	208 0.6×	45 0.2×	328 1.9×	7 0.0×	23 0.2×	7	907
Chunhua Xi China	13	259 0.7×	15 0.1×	93 0.5×	21 0.1×	92 0.8×	35	510
G. Taddei Italy	14	249 0.7×	75 0.4×	32 0.2×	40 0.3×	13 0.1×	26	616
Marta Lorenzo Spain	17	212 0.6×	93 0.5×	322 1.8×	58 0.4×	48 0.4×	30	693
Alfredo Löhr Brazil	11	159 0.4×	36 0.2×	34 0.2×	68 0.5×	11 0.1×	26	471
Paolo Spina Italy	10	104 0.3×	68 0.4×	67 0.4×	63 0.4×	32 0.3×	38	489
Nigel Mendoza United Kingdom	16	49 0.1×	45 0.2×	32 0.2×	50 0.3×	35 0.3×	36	628

Countries citing papers authored by Joy Yang Ge

Since Specialization

Citations

This map shows the geographic impact of Joy Yang Ge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joy Yang Ge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joy Yang Ge more than expected).

Fields of papers citing papers by Joy Yang Ge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joy Yang Ge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joy Yang Ge. The network helps show where Joy Yang Ge may publish in the future.

Co-authorship network of co-authors of Joy Yang Ge

This figure shows the co-authorship network connecting the top 25 collaborators of Joy Yang Ge. A scholar is included among the top collaborators of Joy Yang Ge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joy Yang Ge. Joy Yang Ge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cho, Byoung Chul, Irene Braña, Beatriz Cirauqui, et al.. (2024). Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study. BMC Cancer. 23(S1). 1254–1254. 5 indexed citations

Anderson, Keaven M., Yujie Zhao, Nan Xiao, Joy Yang Ge, & Harlan F. Weisman. (2024). Some Group Sequential Trials from Industry over the Last 30 Years. Statistics in Biopharmaceutical Research. 16(3). 281–293.

Harrington, Kevin J., Ezra E.W. Cohen, Denis Soulières, et al.. (2023). Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence. Oral Oncology. 147. 106587–106587. 7 indexed citations

Ge, Joy Yang. (2023). Evaluation of Pre-Ablation NLR and LMR as Predictors of Distant Metastases in Patients with Differentiated Thyroid Cancer. Acta Endocrinologica (Bucharest). 19(2). 215–220. 1 indexed citations

Bratland, Åse, Eva Muñoz‐Couselo, Laurent Mortier, et al.. (2023). Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629. Dermatology and Therapy. 13(12). 3165–3180. 1 indexed citations

Harrington, Kevin J., Ezra E.W. Cohen, L.L. Siu, et al.. (2022). Phase 2 LEAP-009: Lenvatinib (Lenva) With or Without Pembrolizumab (Pembro) vs. Chemotherapy (Chemo) for Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That has Progressed on Platinum and Immunotherapy. International Journal of Radiation Oncology*Biology*Physics. 112(5). e43–e44. 2 indexed citations

Polewski, Monika D., Malinka Jansson, Kenneth Emancipator, et al.. (2021). Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Head and Neck Squamous Cell Carcinoma. 5(1). 9–17. 2 indexed citations

Harrington, Kevin J., Ezra E.W. Cohen, Lillian L. Siu, et al.. (2021). P-94 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009. Oral Oncology. 118. 10–11. 1 indexed citations

Chan, Anthony T.�C., Victor Lee, M-J. Ahn, et al.. (2021). 858O Results of KEYNOTE-122: A phase III study of pembrolizumab (pembro) monotherapy vs chemotherapy (chemo) for platinum-pretreated, recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC). Annals of Oncology. 32. S786–S786. 24 indexed citations

10.

Zhou, C.Z., J. Feng, Shenglin Ma, et al.. (2020). 1262P Randomized, open-label phase III study of pembrolizumab (pembro) vs docetaxel (doce) in patients (pts) with previously treated NSCLC with PD-L1 tumour proportion score (TPS) ≥1%: KEYNOTE-033. Annals of Oncology. 31. S816–S816. 6 indexed citations

11.

Harrington, Kevin J., Ezra E.W. Cohen, L.L. Siu, et al.. (2020). 351 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009. SHILAP Revista de lepidopterología. A214.1–A214. 2 indexed citations

12.

Si, Lu, X. Zhang, Yongqian Shu, et al.. (2018). KEYNOTE-151: A phase Ib study of second-line pembrolizumab (Pembro) for Chinese patients (pts) with advanced or metastatic melanoma. Annals of Oncology. 29. viii448–viii448. 1 indexed citations

13.

Siu, Lillian L., Lisa Licitra, Chia‐Jui Yen, et al.. (2018). Abstract CT163: KEYNOTE-412: Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma. Cancer Research. 78(13_Supplement). CT163–CT163. 4 indexed citations

14.

Zhou, C.Z., Christian Caglevic, Jianying Zhou, et al.. (2017). KEYNOTE-033: Phase 3 study of pembrolizumab versus docetaxel in patients with previously treated non–small-cell lung cancer (NSCLC). Annals of Oncology. 28. x143–x143. 3 indexed citations

15.

Machiels, J-P., C-J. Yen, Lisa Licitra, et al.. (2017). Phase 3 KEYNOTE-412 trial: Pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Annals of Oncology. 28. xi28–xi28.

16.

Langer, Corey J., Shirish M. Gadgeel, Hossein Borghaei, et al.. (2017). MA09.02 Pembrolizumab + Carboplatin and Pemetrexed as 1st-Line Therapy for Advanced Non–Small Cell Lung Cancer: KEYNOTE-021 Cohort G. Journal of Thoracic Oncology. 12(1). S391–S392. 1 indexed citations

17.

Herring, W. Joseph, et al.. (2017). Orexin Receptor Antagonism in Painful Diabetic Neuropathy. Clinical Journal of Pain. 34(1). 37–43. 7 indexed citations

18.

Mateos, María‐Victoria, Robert Z. Orlowski, David S. Siegel, et al.. (2016). Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): Final efficacy and safety analysis.. Journal of Clinical Oncology. 34(15_suppl). 8010–8010. 40 indexed citations

19.

Yen, Chung‐Jen, Ezra E.W. Cohen, Jan B. Vermorken, et al.. (2015). 342TiP Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048. Annals of Oncology. 26. ix93–ix93. 1 indexed citations

20.

Cohen, Ezra E.W., Jan B. Vermorken, Kevin J. Harrington, et al.. (2015). Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048. Annals of Oncology. 26. viii5–viii5. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact